EraCal Therapeutics Ltd.

The biotech-company EraCal Therapeutics Ltd. is a spin-off from the University of Zurich and Harvard University. The company is privately held by a biotech-specialized investor base incl. BERNINA BioInvest, Redalpine, and UZH Life Sciences Fund.


Board of Directors


A. Kessler Ph.D.


Ann Kessler held various senior research positions at Roche for over 26 years. She launched the obesity research program, led its clinical development, and brought orlistat (Alli, Xenical) to the market.


Prof. HR. Künzle


Hans Rainer Künzle is a Founding Partner of Kendris Ltd. After his retirement, he continues as a member of the Board of Directors of Kendris Ltd. and he serves his clients as Of Counsel.


B. Ernst Ph.D.

Board Member

Bettina Ernst is a biotech entrepreneur and investor. She serves the Swiss Biotech community in various roles thanks to her deep experience in medical research in the US and Europe.


J. Jordi Ph.D.

Board Member

Josua Jordi is the Chief Executive Officer of EraCal Therapeutics. Ltd and leads its development since inception.


Scientific Advisory Board


H. Böttcher Ph.D.

Henning Böttcher is the former head of medicinal chemistry at Merck KGaA. He has a track record of bringing several new chemical entities deep into clinical development or to the market such as the anti-depressant vilazodone (Viibryd).

Meyer Druck.jpg

G. Meyer Ph.D.

Gerd Meyer is Head of Plexus Ventures CH, a leading global development & licensing firm. He held various senior positions at Novartis Pharma’s R&D, BD&L/M&A and in Business Functions, where he licensed and launched important drugs.


Prof. F. Engert

Florian Engert is a neuroscience expert and tenured professor at Harvard University. His work established the larval zebrafish as a vertebrate animal model for the systematic examination of neural circuits in control of behavior.


Prof. T. A. Lutz

Thomas A. Lutz is an obesity and diabetes expert and tenured professor at the University of Zurich. His research focuses on the peptide hormone amylin, of which the analog pramlintide (Symlin) is FDA-approved for diabetes.




J. Jordi Ph.D.

Chief Executive Officer

Josua Jordi is a biochemist ETH by training and completed a Ph.D. in physiology at the University of Zurich. He developed EraCal’s platform as a postdoctoral fellow at Harvard University. The translation proof of concept for the zebrafish platform was achieved at the University of Zurich.


S. Breitler Ph.D.

Chief Operational Officer

Simon Breitler holds a Ph.D. in synthetic organic chemistry from ETH Zurich which was complemented with a fellowship at Harvard University. During his 2.5 years at the preclinical chemistry, manufacturing, and control (CMC) department at Roche, he acquired the necessary skills and knowledge for his responsibilities as leader of the technical development of EraCal's pipeline.